J. Goldman & CO LP Biogen Inc. Call Options Transaction History

J. Goldman & CO LP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$190.52 - $236.72 $3.81 Million - $4.73 Million	20,000 Added 100.0%	40,000 $9.27 Million
Q1 2024 May 15, 2024	BUY	$212.02 - $267.71 $4.24 Million - $5.35 Million	20,000 New	20,000 $4.31 Million
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $19.9 Million - $22.7 Million	-77,500 Reduced 81.58%	17,500 $4.87 Million
Q4 2022 Feb 14, 2023	BUY	$252.44 - $306.72 $19.9 Million - $24.1 Million	78,700 Added 482.82%	95,000 $26.3 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $3.17 Million - $4.38 Million	16,300 New	16,300 $4.35 Million
Q1 2021 May 17, 2021	SELL	$242.95 - $284.63 $8.75 Million - $10.2 Million	-36,000 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$236.26 - $355.63 $8.51 Million - $12.8 Million	36,000 New	36,000 $8.82 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.